查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1861433

登革熱檢測市場按檢測類型、技術、最終用戶、產品類型、安裝環境和檢體類型分類－全球預測（2025-2032 年）

Dengue Testing Market by Test Type, Technology, End User, Product Type, Setting, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，登革熱檢測市場規模將達到 8.3512 億美元，複合年成長率為 5.92%。

關鍵市場統計數據
基準年 2024 5.2702億美元
預計年份：2025年 5.5861億美元
預測年份 2032 8.3512億美元
複合年成長率 (%) 5.92%

我們將介紹目前的登革熱診斷環境，包括不斷發展的檢測方法、實施挑戰以及在醫療環境中進行臨床判斷的必要性。

由於科技的快速發展、醫療服務模式的變革以及公共衛生重點的調整，登革熱診斷正處於關鍵時刻。儘管準確快速的檢測仍然是有效臨床管理和疫情控制的基礎，但從血清學、抗原檢測到分子檢測等多種檢測方法的多樣性，給臨床醫生、實驗室技術人員和採購經理帶來了複雜的決策環境，需要在臨床需求、營運限制和監管要求之間進行周密的協調。

傳統上，基於實驗室的分子診斷平台提供最高的分析靈敏度，而照護現場抗原檢測則側重於速度和便利性。然而，隨著側向流動化學、微陣列平台和即時聚合酵素鏈鎖反應儀器等技術的進步，這些差異正在變得模糊，性能、單次檢測成本和部署靈活性方面的差距正在縮小。同時，全球分散式檢查和強化監測的趨勢，推動了對檢驗於多種檢體（包括血漿、血清和全血）的檢測方法的需求，以及對能夠與電子健康系統整合以實現病例報告和流行病學監測的解決方案的需求。

在此背景下，相關人員需要權衡臨床績效指標（例如靈敏度、特異性和檢測窗口）與實際操作因素（例如檢測量、低溫運輸要求以及診所和照護現場的培訓需求）。隨著登革熱在流行地區和新確診地區持續出現，選擇和部署適合當地實驗室基礎設施和患者診療流程的診斷方法，將是降低發病率和最佳化資源利用的關鍵因素。

快速的平台創新、檢測的去中心化以及不斷變化的監管法規正在重塑診斷路徑，並加速其在整個醫療保健系統中的應用。

過去五年，登革熱檢測的研發、檢驗和應用方式發生了突破性變革。檢測化學和平台工程的進步提升了多種檢測方法的分析性能，使得抗原檢測能夠更快地獲得結果，分子檢測能夠提高通量並實現自動化。同時，數位轉型也在推動診斷設備與實驗室資訊系統的連接，從而實現即時報告並整合到監控網路中。最終，一個響應更迅速的診斷生態系統得以構建，能夠更有效地支持疫情爆發檢測和臨床分診。

同時，檢測分散化趨勢顯著。簡化的工作流程和較低的訓練要求促使快速抗原和抗體檢測在照護現場和門診診所得到更廣泛的應用。攜帶式PCR儀和讀數儀的投資也推動了這一轉變，使分子檢測能夠在患者附近進行。因此，醫療系統正在重新評估其診斷流程，以平衡快速篩檢檢測和分子確診檢測，從而在確保診斷準確性的同時最佳化資源配置。

市場動態也受到新的監管路徑和對實際應用效能數據日益重視的影響。衛生部門正著重進行上市後監測和有條件核准，優先考慮在不影響可靠性的前提下實現快速獲取。同時，診斷試劑生產商、學術團體和公共衛生機構之間的策略聯盟正在加速檢驗研究，並推動創新檢測方法的快速部署。這些變化共同推動了登革熱檢測方法的轉變，使其更加靈活、協作和臨床整合，並優先考慮速度、準確性和操作適用性。

評估2025年美國關稅對供應鏈調整、採購應對措施以及診斷性採購和營運的策略影響

美國將於2025年實施的新關稅，為採購登革熱診斷組件和成品檢測套組的機構帶來了更多挑戰。這些針對進口設備、試劑和部分檢測套組組件的關稅，增加了從受影響地區採購某些物品的直接成本，迫使採購團隊重新評估籌資策略和總到岸成本。供應商和醫療系統正在透過重新評估其供應商組合、探索區域性生產替代方案以及重組分銷協議來應對這一挑戰，以減輕眼前的成本負擔。

除了採購成本壓力外，關稅環境也影響供應鏈設計和庫存管理。國內供應選擇有限的企業正在提高安全庫存水準並延長計畫週期，以應對進口成本波動和潛在的前置作業時間延長。同時，供應商正在加快關鍵設備（例如讀數儀和聚合酵素連鎖反應熱迴圈儀）以及重要耗材和試劑的本地化生產，但這些努力需要資金投入和時間才能實施。在此期間，一些買家正在談判長期合約以確保以可預測的價格獲得供應，而另一些買家則正在分散供應商來源以降低風險。

關稅引發的重組也影響競爭格局。擁有垂直整合供應鏈和本地生產基地的製造商透過提供更穩定的價格和更短的前置作業時間，獲得了比較優勢。同時，依賴跨境採購的小型供應商則面臨證明其定價合理性和確保供應連續性的壓力。受預算限制的公共衛生項目和醫院尤其容易受到這些變化的影響，它們正在重新評估其採購優先事項。這包括轉向那些具有成本效益的臨床效用並最大限度減少對受關稅影響的投入品依賴的檢測方法和平台。

基於深度細分的診斷洞察，解釋了測試類型、技術、最終用戶、產品形式、安裝環境和檢體基質如何決定實施選擇。

了解市場區隔動態對於選擇合適的診斷策略以及使產品系列與使用者需求相符至關重要。從檢測類型、抗體、抗原和分子檢測選項的角度分析市場格局，可以清楚地展現臨床和操作方面的權衡取捨。抗體檢測（分為IgG和IgM檢測）在先前接觸評估和血清流行病學調查中發揮重要作用，而抗原檢測（包括NS1酵素免疫分析法和快速NS1檢測）的優勢在於其快速性，有助於早期發現。分子檢測，包括常規PCR和即時PCR，仍然是確診的標準方法，需要高分析靈敏度和基因型資訊。

技術細分也會影響檢測方法的應用。酵素免疫分析法）仍然是高通量檢測的基礎，而採用膠體金或螢光檢測技術的側向流動免疫檢測則能夠實現真正的即時檢測，並提供一系列定量分析功能。微陣列平台增加了多重偵測功能，可用於鑑別診斷和監測。聚合酵素鏈鎖反應）技術，從傳統方法到即時方法，為靈敏、特異性的病毒檢測提供了基礎，從而為臨床決策和監測提供資訊。

最終用戶的考量也影響產品的選擇和實施策略。診所和照護現場環境傾向於快速、易用且對設備依賴性低的檢測方式。診斷實驗室優先考慮檢測的可重複性和通量。醫院則需要在快速分診和確診檢測之間尋求平衡。研究實驗室需要能夠支援方法靈活性和深度分析的平台。按產品類型分類，可以突顯互補的商業性模式。儀器和讀數器，包括聚合酵素連鎖反應熱迴圈儀和數位讀數器，支援平台相關的檢測。軟體解決方案則實現連接、數據分析和結果管理。檢測套組提供常規檢測操作所需的耗材。最後，安裝環境和檢體類型的選擇會影響物流和檢驗策略。中心實驗室提供可控環境以支援複雜的工作流程，而照護現場環境則需要檢測方法在血漿、血清和全血等不同基質上的穩健性。綜合考慮這些細分維度，可以發現哪些領域的設備、生物化學和營運支援方面的投資能夠帶來最大的臨床和商業性回報。

區域診斷重點和實施實務決定了採購和部署策略。

區域趨勢將影響診斷方法的優先排序、檢驗和採購方式。美洲、歐洲、中東和非洲以及亞太地區的實際情況各不相同。在美洲，成熟的檢測網路和積極的私營部門參與有利於採用混合模式，將集中式分子檢測與分散式檢查檢測相結合，並輔以門診和急診環境下的照護現場抗原檢測。某些國家的法規結構為緊急使用和上市後監測提供了明確的途徑，使製造商能夠在展示實際應用性能的同時擴大分銷範圍。

歐洲、中東和非洲地區各國監管體系和醫療基礎設施的差異導致了檢測方法應用模式的多樣性。歐洲資源豐富的市場優先考慮統一的檢驗標準以及與電子健康記錄的整合，而中東和北非地區的市場則常常面臨物流方面的限制，因此對能夠承受低溫運輸環境波動的、堅固耐用且維護成本低的檢測套組和照護現場平台有著很高的需求。聯合採購機制和捐助者支持的舉措在擴大資源匱乏地區檢測服務的可近性方面發揮關鍵作用。

亞太地區對大都會圈的高通量檢測解決方案和地方性流行區分散診所的快速診斷方案的需求都非常強勁。該地區多個國家已發展出本地生產能力，這影響著價格和供應穩定性。跨境合作和區域監測網路正在不斷加強，促進了數據共用和協調一致的應對策略。綜上所述，這些區域特徵凸顯了診斷選擇和部署策略需要根據當地的基礎設施、監管路徑和流行病學情況進行調整，以實現有效的病例發現和公共衛生影響。

診斷公司如何調整產品系列、生產彈性和數位化能力，以提供一體化的登革熱檢測解決方案並確保其供應鏈安全

登革熱診斷生態系統中的主要企業和創新者正透過投資產品研發、建立策略夥伴關係關係以及提升生產能力，來因應不斷湧現的新需求。這些公司擁有涵蓋抗原、抗體和分子診斷的多元化產品系列，能夠滿足多層次的臨床路徑需求，提供即時快速篩檢和中心實驗室確診檢測。檢測開發人員和設備製造商之間的策略聯盟正在加速整合解決方案的交付，從而減輕終端用戶的檢驗負擔，並加快臨床應用進程。

商業策略日益強調互聯互通和軟體服務，以提升診斷平台的效用。一些公司提供的解決方案將讀數器和聚合酵素連鎖反應熱迴圈儀與安全的數據管理系統結合，從而能夠更有效率地收集和分析測試數據，有助於改善病例追蹤和資源分配。此外，投資本地生產或建立分散式製造夥伴關係的製造商也獲得了實際的好處，例如在供應連續性和應對力關稅和物流中斷方面的能力。

我們也看到市場推廣策略的創新。透過培訓、在地化檢驗協助和全面的服務協議為最終用戶提供支援的機構，降低了准入門檻，促進了產品的長期應用。規模較小的專業開發公司透過提供可授權或與主要平台供應商聯合品牌的利基或高效能檢測產品，為生態系統做出了貢獻。總而言之，這些舉措凸顯了解決方案正朝著整合檢測化學、硬體和數位基礎設施的方向發展，以滿足不同醫療保健環境的實際需求。

為診斷產業領導者提供切實可行的策略步驟，以加強供應鏈、加速照護現場創新並整合數位化連接，從而推動技術應用。

產業領導者應迅速調整產品開發、供應鏈策略和客戶參與，以適應登革熱診斷領域不斷變化的實際情況。首先，應優先考慮採購多元化，並探索區域製造夥伴關係，以降低關稅造成的成本波動風險，並縮短關鍵試劑和儀器組件的前置作業時間。投資於靈活的生產合約和雙通路採購策略將確保供應的連續性，並增強供應商的議價能力。其次，為了滿足快速分流和分散式監測的需求，他們應加快開發和推出與讀卡機相容的照護現場抗原檢測和側向層析檢測，同時保留用於確診和基因分型的實驗室級分子檢測方案。

領導者還需將數位化措施融入其產品藍圖。在設備和閱讀器中建立連接性和標準化的數據導出功能，將有助於即時病例報告，提升公共衛生情報水平，並創造附加價值服務機會。同時，他們將專注於終端用戶支持，設計簡化的工作流程，提供全面的驗證方案，並投資培訓項目，以降低用戶採用的門檻。從商業性角度來看，他們將提供靈活的合約模式，充分考慮公共衛生專案和醫院的採購週期，包括按績效付費合約以及包含設備、耗材和軟體服務的捆綁式解決方案。

最後，積極與監管機構和公共衛生相關人員合作，設計反映真實世界應用的檢驗研究，包括對血漿、血清和全血的評估，以及在中心實驗室和照護現場環境中的評估。透明的上市後監測和可靠的真實世界證據將有助於建立信任並促進更廣泛的應用。這些綜合努力將使企業能夠在競爭日益激烈和分散的環境中實現臨床相關性、維持供應安全並推動永續成長。

採用嚴謹的混合方法研究途徑，結合專家訪談、實驗室檢驗審查、法規分析和供應鏈圖譜，以產生以營運為導向的洞見。

本研究採用結構化的混合方法，綜合運用質性專家訪談、實驗室檢驗審查、監管指南分析以及對同行評審文獻和技術白皮書的系統性回顧等方法，對證據進行綜合分析。研究重點包括與臨床實驗室技術人員、感染疾病專家、採購人員和診斷試劑開發人員進行對話，以收集他們對檢測性能、操作限制和實施注意事項的現場觀點。實驗室檢驗審查檢驗了代表抗體、抗原和分子檢測類別的檢測方法的報告分析靈敏度、特異性和操作特性，並重點關注檢體基質的適用性和儀器要求。

我們分析了監管指南和政策文件，以了解影響部署時間的因素，例如核准流程、緊急使用法規和上市後監測要求。該調查方法還包括供應鏈圖譜分析，以確定設備、耗材和試劑的採購依賴關係，並評估關稅和物流中斷帶來的風險。在條件允許的情況下，我們對多個資料來源進行了三角驗證，以提高結論的可靠性，並突出顯示證據有限或不一致的領域。

此調查方法固有的限制包括不同測試類型效能資料的品質和可用性存在差異，以及監管決策和供應鏈狀況的快速變化。為彌補這些局限性，本研究優先收集關鍵相關人員的意見，並將測試結果與多個獨立資訊來源進行檢驗。最終的分析旨在提供具有實際操作價值的綜合資訊，而非最終的技術檢驗，並協助決策者制定兼顧臨床和物流因素的實施計劃和籌資策略。

對診斷創新、營運完整性和供應鏈韌性進行全面綜合分析，以確定有效的登革熱檢測策略和專案優先事項。

技術創新、去中心化和供應鏈重組的整合，為登革熱診斷帶來了機會和營運挑戰。快速抗原檢測和改進的側向層析檢測提高了即時病例檢測能力，而PCR設備和實驗室自動化技術的進步則維持了密集型確診檢測和基因型監測的必要性。同時，貿易政策變化等外部因素使得供應鏈韌性和籌資策略成為決定採購風險和專案連續性的關鍵因素。

對於從業人員和決策者而言，需求顯而易見：診斷選擇必須與臨床路徑和實際操作相符。這需要對檢測類型和技術的優缺點進行嚴格評估，制定謹慎的籌資策略以減輕外部成本壓力，並投資於數位化和培訓基礎設施以減少實施阻力。採用整合式方法，結合可靠的就地檢驗、必要時的實驗室確認以及數據協作的機構，將更有利於維持診斷的連續性，並支持有效的臨床和公共衛生應對措施。

展望未來，診斷技術開發商、醫療系統和監管機構之間持續合作對於將創新成果轉化為可及可靠的檢測方案至關重要。優先考慮供應鏈多元化、真實世界檢驗和以用戶為中心的產品設計的相關人員將加速檢測技術的普及應用，並改善登革熱患者和社區的治療效果。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 在現場環境中實施與智慧型手機相容的登革熱血清分型快速分子檢測
  • 開發一種可同時檢測登革熱病毒、茲卡和基孔肯雅病毒的多重照護現場診斷方法
  • 整合基於 CRISPR-Cas 的螢光檢測方法快速檢測登革病毒 RNA（在照護端實施）
  • 利用奈米顆粒增強檢測技術的高靈敏度免疫檢測法在資源匱乏地區登革熱早期診斷的應用
  • 監管核准趨勢加速家用登革熱抗原檢測套組的商業化，並實現數位化報告
  • 利用人工智慧驅動的演算法，分析患者症狀和檢測結果，即時預測登革熱熱點地區
  • 透過生物技術公司與公共衛生機構的合作模式，利用行動偵測單元擴大登革熱流行地區的監測範圍

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 登革熱檢測市場（依檢測類型分類）

  • 抗體檢測
    • IgG抗體檢測
    • IgM抗體檢測
  • 抗原檢測
    • Ns1酵素免疫分析法
    • Ns1快速檢測
  • 分子檢測
    • 常規聚合酵素鏈鎖反應
    • 即時聚合酵素鏈鎖反應

9. 按技術分類的登革熱檢測市場

  • 酵素免疫分析法
  • 側向流動免疫檢測
    • 膠體金法
    • 螢光免疫分析
  • 微陣列技術
  • 聚合酵素鏈鎖反應
    • 常規聚合酵素鏈鎖反應
    • 即時聚合酵素鏈鎖反應

第10章 依最終用戶分類的登革熱檢測市場

  • 診所
  • 診斷實驗室
  • 醫院
  • 研究所

第11章 登革熱檢測市場（依產品類型分類）

  • 裝置
    • 領導者
    • 聚合酵素連鎖反應熱迴圈儀
  • 軟體解決方案
  • 檢測套組

第12章：登革熱檢測市場（按地區分類）

  • 中心實驗室
  • 照護端

13. 依檢體類型分類的登革熱檢測市場

  • 電漿
  • 血清
  • 全血

14. 各地區的登革熱檢測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 登革熱檢測市場（依群體分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各國登革熱檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Abbott Laboratories
    • F. Hoffmann-La Roche Ltd
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • bioM 9rieux SA
    • QIAGEN NV
    • Bio-Rad Laboratories, Inc.
    • Siemens Healthineers AG
    • Meridian Bioscience, Inc.
    • Chembio Diagnostics, Inc.
Product Code: MRR-69324464D0E5

The Dengue Testing Market is projected to grow by USD 835.12 million at a CAGR of 5.92% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 527.02 million
Estimated Year [2025] USD 558.61 million
Forecast Year [2032] USD 835.12 million
CAGR (%) 5.92%

Introducing the current dengue diagnostics environment with evolving assay modalities, deployment challenges, and clinical decision imperatives across care settings

Dengue diagnostic capabilities are at a pivotal juncture, shaped by rapid technological progress, shifting care delivery models, and evolving public health priorities. Accurate and timely detection remains foundational to effective clinical management and outbreak control, while the diversity of available assays-from serology to antigen detection to molecular methods-creates a complex decision environment for clinicians, laboratorians, and procurement leaders. The landscape demands careful calibration between clinical needs, operational constraints, and regulatory expectations.

Historically, laboratory-based molecular platforms provided the highest analytical sensitivity, contrasted with point-of-care antigen assays that emphasized speed and simplicity. However, these distinctions are blurring as innovations in lateral flow chemistry, microarray platforms, and real-time polymerase chain reaction instruments narrow gaps in performance, cost per test, and deployment flexibility. In parallel, the global push toward decentralized testing and stronger surveillance has increased demand for assays validated on a range of sample types including plasma, serum, and whole blood, and for solutions that integrate with electronic health systems to enable case reporting and epidemiological monitoring.

Against this backdrop, stakeholders must balance clinical performance metrics such as sensitivity, specificity, and window-of-detection with pragmatic considerations including throughput, cold-chain requirements, and training needs at clinics and point-of-care settings. As dengue continues to circulate in endemic and newly exposed regions, the capacity to choose and implement diagnostics that align with local laboratory infrastructure and patient pathways will be a defining factor in limiting morbidity and optimizing resource use.

How rapid platform innovation, decentralization of testing, and regulatory evolution are reshaping diagnostic pathways and accelerating adoption across healthcare systems

The past five years have seen transformative shifts that are redefining how dengue testing is developed, validated, and delivered. Advances in assay chemistry and platform engineering have lifted analytical performance across multiple categories, enabling antigen tests with faster time-to-result and molecular tests with greater throughput and automation. These technology improvements are being accompanied by digital transformations that connect diagnostic devices to laboratory information systems, enabling real-time reporting and integration into surveillance networks. The result is a more responsive diagnostic ecosystem that can better support outbreak detection and clinical triage.

Simultaneously, there has been a marked movement toward decentralization of testing. Point-of-care settings and outpatient clinics are increasingly equipped to perform rapid antigen and antibody assays, facilitated by simpler workflows and lower training requirements. This shift is complemented by investments in portable PCR instruments and reader devices that allow molecular-level confirmation closer to the patient. As a consequence, healthcare systems are re-evaluating diagnostic algorithms to balance the use of rapid screening assays with confirmatory molecular testing, optimizing resource allocation while preserving diagnostic confidence.

Market dynamics have also been influenced by new regulatory pathways and emphasis on real-world performance data. Health authorities are leaning on post-market surveillance and conditional approvals that prioritize timely access without sacrificing reliability. In parallel, strategic partnerships among diagnostics manufacturers, academic groups, and public health agencies are accelerating validation studies, enabling faster adoption of innovative assays. Taken together, these changes are driving a more agile, connected, and clinically integrated approach to dengue testing that prioritizes speed, accuracy, and operational fit.

Assessing the 2025 United States tariff-induced supply chain adjustments, procurement responses, and strategic implications for diagnostic sourcing and operations

The introduction of new tariffs in the United States in 2025 has introduced a layer of complexity for organizations procuring dengue diagnostic components and finished assays. Tariff measures applied to imported instruments, reagents, and certain assay components have increased the direct cost of sourcing specific items from affected jurisdictions, prompting procurement teams to re-assess sourcing strategies and total landed cost. Suppliers and health systems have responded by reevaluating supplier portfolios, seeking regional manufacturing alternatives, and restructuring distribution agreements to mitigate immediate cost exposure.

Beyond procurement cost pressures, the tariff environment has influenced supply chain design and inventory management. Organizations with limited domestic supply options have increased safety stock levels and extended planning horizons to buffer against import cost volatility and potential lead-time increases. Suppliers have accelerated efforts to localize production of critical inputs, including readers and thermal cyclers, as well as key consumables and reagents, though such initiatives require capital investment and time to realize. In the interim, some buyers have negotiated longer-term contracts to secure supply at predictable prices, while others have diversified their supplier base to distribute risk.

The tariff-driven reconfiguration has also affected competitive dynamics. Manufacturers with vertically integrated supply chains or local production footprints are gaining relative advantage, as they can offer more stable pricing and shorter lead times. Conversely, smaller suppliers reliant on cross-border sourcing face pressure to justify pricing and demonstrate continuity of supply. Public health programs and hospitals operating under constrained budgets are particularly exposed to these shifts, prompting re-prioritization of procurement toward assays and platforms that deliver the most clinical utility per dollar and that minimize exposure to tariff-affected inputs.

Deep segmentation-driven diagnostic insights describing how test types, technologies, end users, product formats, settings, and sample matrices determine deployment choices

Understanding segmentation dynamics is essential to selecting appropriate diagnostic strategies and aligning product portfolios with user needs. When viewing the landscape through the lens of test type, there are clear clinical and operational trade-offs among antibody, antigen, and molecular options. Antibody testing, split into IgG and IgM assays, serves useful roles in retrospective exposure assessment and seroprevalence work, while antigen testing-comprising NS1 enzyme-linked immunosorbent assays and rapid NS1 tests-supports early detection with the benefit of speed. Molecular testing, including conventional PCR and real-time PCR approaches, remains the standard for confirmation where high analytical sensitivity and genotype information may be required.

Technological segmentation further influences adoption. Enzyme-linked immunosorbent assays continue to underpin high-throughput laboratory operations, whereas lateral flow immunoassays, differentiated by colloidal gold or fluorescent readouts, enable true point-of-care deployment with varying degrees of quantitative capacity. Microarray platforms add multiplexing capabilities that are valuable in differential diagnosis scenarios and in research settings, and polymerase chain reaction technologies, from conventional to real-time formats, provide the backbone for sensitive and specific viral detection that informs clinical decision-making and surveillance.

End-user considerations also drive product selection and implementation strategies. Clinics and point-of-care environments favor rapid, user-friendly formats with minimal instrument dependence; diagnostic laboratories emphasize assay reproducibility and throughput; hospitals balance the need for both rapid triage and confirmatory testing streams; and research institutes require platforms that support methodological flexibility and in-depth analyses. Product type segmentation highlights complementary commercial approaches: instruments and readers, which include thermal cyclers and digital readers, underpin platform-dependent assays; software solutions enable connectivity, data analytics, and results management; and test kits deliver the consumables required for routine testing operations. Finally, setting and sample type choices shape logistics and validation strategies, with central laboratories providing controlled environments that support complex workflows and point-of-care settings necessitating robustness across plasma, serum, and whole blood matrices. An integrated view across these segmentation dimensions reveals where investment in instrumentation, biochemical chemistry, and operational enablement will yield the greatest clinical and commercial returns.

Regional diagnostic priorities and implementation realities across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape procurement and deployment strategies

Regional dynamics shape how diagnostics are prioritized, validated, and procured, with distinct operational realities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established laboratory networks and considerable private-sector participation favor a mixed model of centralized molecular testing supplemented by point-of-care antigen testing in outpatient and emergency settings. Regulatory frameworks in certain countries provide clear pathways for emergency use and post-market surveillance, enabling manufacturers to scale distribution while demonstrating real-world performance.

Europe, the Middle East & Africa present a mosaic of adoption patterns influenced by national regulatory regimes and heterogeneous healthcare infrastructures. High-resource markets in Europe emphasize harmonized validation standards and integration with electronic health records, while markets across the Middle East and Africa often grapple with logistical constraints that drive demand for robust, low-maintenance assays and point-of-care platforms that tolerate variable cold-chain conditions. Collaborative procurement mechanisms and donor-supported initiatives play a meaningful role in driving access in lower-resource settings.

Asia-Pacific exhibits strong demand for both high-throughput laboratory solutions in metropolitan centers and rapid diagnostic options for decentralized clinics across endemic regions. Several countries in the region have developed local manufacturing capacity, which influences pricing and supply resiliency. Cross-border collaboration and regional surveillance networks have strengthened, fostering data sharing and harmonized response strategies. Taken together, these regional characteristics underline that diagnostic selection and deployment strategies must be tailored to local infrastructure, regulatory pathways, and epidemiological context to achieve effective case detection and public health impact.

How diagnostics companies are aligning product portfolios, manufacturing resilience, and digital capabilities to deliver integrated dengue testing solutions and secure supply chains

Leading firms and innovators in the dengue diagnostics ecosystem are responding to emergent needs through a combination of product development, strategic partnerships, and investments in manufacturing resilience. Companies with diversified portfolios that span antigen, antibody, and molecular offerings are positioned to meet multi-tiered clinical pathways, providing rapid screening at point-of-care and confirmatory testing in centralized laboratories. Strategic collaborations between assay developers and instrument manufacturers have accelerated the availability of integrated solutions that reduce validation burden for end users and shorten time-to-clinic deployment.

Commercial strategies increasingly emphasize connectivity features and software-enabled services that enhance the utility of diagnostic platforms. Companies that offer readers or thermal cyclers paired with secure data management systems enable laboratories and public health agencies to collect and analyze testing data more efficiently, improving case tracking and resource allocation. In addition, manufacturers that have invested in regional production or established distributed manufacturing partnerships are seeing tangible benefits in terms of supply continuity and responsiveness to tariff- or logistics-driven disruptions.

Innovation is also manifest in go-to-market approaches. Organizations that support end users through training, localized validation support, and bundled service agreements reduce implementation friction and build long-term adoption. Smaller specialized developers contribute to the ecosystem by delivering niche or high-performance assays that can be licensed or co-branded with larger platform providers. Collectively, these corporate behaviors underscore a shift toward integrated solutions that combine assay chemistry, hardware, and digital infrastructure to meet the practical demands of diverse healthcare environments.

Actionable strategic steps for diagnostics leaders to strengthen supply chains, accelerate point-of-care innovation, and integrate digital connectivity to drive adoption

Industry leaders should act decisively to align product development, supply chain strategy, and customer engagement with the evolving realities of dengue diagnostics. First, prioritize diversification of sourcing and consider regional manufacturing partnerships to reduce exposure to tariff-induced cost volatility and to shorten lead times for critical reagents and instrument components. Investing in flexible manufacturing contracts and dual-sourcing strategies will preserve continuity and create negotiating leverage with suppliers. Next, accelerate development and market readiness of point-of-care antigen and lateral flow formats with reader compatibility to meet demand for rapid triage and decentralized surveillance, while maintaining laboratory-grade molecular options for confirmatory testing and genotype analysis.

Leaders must also integrate digital enablement into product roadmaps. Embedding connectivity and standardized data export capabilities within instruments and readers will facilitate real-time case reporting, contribute to public health intelligence, and create value-added service opportunities. Concurrently, focus on end-user enablement by designing simplified workflows, providing comprehensive validation packages, and investing in training programs that reduce adoption friction. From a commercial perspective, offer flexible contracting models that account for procurement cycles in public health programs and hospitals, including outcome-oriented agreements and bundled solutions that combine instruments, consumables, and software services.

Finally, engage proactively with regulators and public health stakeholders to design validation studies that reflect real-world performance, including evaluations across plasma, serum, and whole blood, and in both central laboratory and point-of-care settings. Transparent post-market surveillance and robust real-world evidence generation will build trust and facilitate broader adoption. These combined actions will position companies to capture clinical relevance, maintain supply stability, and drive sustainable growth in an increasingly competitive and fragmented environment.

Rigorous mixed-methods research approach combining expert interviews, laboratory validation reviews, regulatory analyses, and supply chain mapping to produce operationally focused insights

This research synthesizes evidence from a structured, mixed-methods approach that combines qualitative expert interviews, laboratory validation reviews, regulatory guidance analyses, and a systematic review of peer-reviewed literature and technical white papers. Primary engagements included conversations with clinical laboratorians, infectious disease specialists, procurement leads, and diagnostic developers to capture frontline perspectives on assay performance, operational constraints, and deployment considerations. Laboratory validation reviews examined reported analytical sensitivity, specificity, and operational characteristics for representative assays across antibody, antigen, and molecular categories, with attention to sample matrix compatibility and instrument requirements.

Regulatory guidance and policy documents were analyzed to understand approval pathways, emergency use provisions, and post-market surveillance expectations that influence time-to-adoption. The methodology also incorporated supply chain mapping to identify sourcing dependencies for instruments, consumables, and reagents, and to assess potential exposure to tariff and logistics disruptions. Where possible, findings were triangulated across data streams to increase confidence in conclusions and to highlight areas where evidence is limited or variable.

Limitations inherent to the methodology include variability in the quality and availability of performance data across assay types and the rapidly evolving nature of regulatory decisions and supply chain conditions. To mitigate these limitations, the research prioritized primary stakeholder input and validated laboratory findings against multiple independent sources. The resulting analysis aims to provide an operationally useful synthesis rather than definitive technical validation, supporting decision-makers in planning implementation and procurement strategies that account for both clinical and logistical considerations.

Concluding synthesis of diagnostic innovation, operational alignment, and supply chain resilience that defines effective dengue testing strategies and program priorities

The convergence of technological innovation, decentralization, and supply chain realignment has created both opportunities and operational challenges for dengue diagnostics. Rapid antigen and improved lateral flow formats are expanding the capacity for timely case detection at the point of care, while advances in PCR instrumentation and laboratory automation sustain the need for centralized confirmatory testing and genotypic surveillance. At the same time, external forces such as trade policy shifts have made supply chain resilience and sourcing strategy primary determinants of procurement risk and program continuity.

For practitioners and decision-makers, the imperative is clear: align diagnostic selection with clinical pathways and operational realities. This requires a nuanced assessment of test type and technology trade-offs, deliberate sourcing strategies to mitigate external cost pressures, and investment in digital and training infrastructure that reduces implementation friction. Organizations that adopt an integrated approach-combining robust point-of-care screening, laboratory confirmation where needed, and data connectivity-will be best positioned to maintain diagnostic continuity and to support effective clinical and public health responses.

Looking ahead, continued collaboration among diagnostic developers, health systems, and regulatory authorities will be essential to translate innovation into accessible, reliable testing programs. Stakeholders who prioritize supply chain diversification, real-world performance validation, and user-centered product design will accelerate adoption and improve outcomes for patients and communities affected by dengue.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of smartphone-enabled rapid molecular assays for dengue serotype differentiation in field settings
  • 5.2. Development of multiplex point-of-care diagnostics detecting dengue, Zika, and chikungunya viruses simultaneously
  • 5.3. Integration of CRISPR-Cas based fluorescence readout tests for rapid dengue viral RNA detection at point of care
  • 5.4. Emergence of high-sensitivity immunoassays utilizing nanoparticle-enhanced detection for early dengue diagnosis in low-resource settings
  • 5.5. Regulatory approval trends accelerating commercialization of at-home dengue antigen test kits with digital reporting capabilities
  • 5.6. Implementation of AI-driven algorithms analyzing patient symptoms and test results to predict dengue outbreak hotspots in real time
  • 5.7. Partnership models between biotech firms and public health agencies to scale dengue surveillance via mobile testing units in endemic regions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dengue Testing Market, by Test Type

  • 8.1. Antibody Test
    • 8.1.1. Igg Antibody Test
    • 8.1.2. Igm Antibody Test
  • 8.2. Antigen Test
    • 8.2.1. Ns1 Enzyme Linked Immunosorbent Assay
    • 8.2.2. Ns1 Rapid Test
  • 8.3. Molecular Test
    • 8.3.1. Conventional Polymerase Chain Reaction
    • 8.3.2. Real Time Polymerase Chain Reaction

9. Dengue Testing Market, by Technology

  • 9.1. Enzyme Linked Immunosorbent Assay
  • 9.2. Lateral Flow Immunoassay
    • 9.2.1. Colloidal Gold Assay
    • 9.2.2. Fluorescent Immunoassay
  • 9.3. Microarray Technology
  • 9.4. Polymerase Chain Reaction
    • 9.4.1. Conventional Polymerase Chain Reaction
    • 9.4.2. Real Time Polymerase Chain Reaction

10. Dengue Testing Market, by End User

  • 10.1. Clinics
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals
  • 10.4. Research Institutes

11. Dengue Testing Market, by Product Type

  • 11.1. Instruments
    • 11.1.1. Readers
    • 11.1.2. Thermal Cyclers
  • 11.2. Software Solutions
  • 11.3. Test Kits

12. Dengue Testing Market, by Setting

  • 12.1. Central Laboratory
  • 12.2. Point Of Care

13. Dengue Testing Market, by Sample Type

  • 13.1. Plasma
  • 13.2. Serum
  • 13.3. Whole Blood

14. Dengue Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Dengue Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Dengue Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Abbott Laboratories
    • 17.3.2. F. Hoffmann-La Roche Ltd
    • 17.3.3. Thermo Fisher Scientific Inc.
    • 17.3.4. Danaher Corporation
    • 17.3.5. bioM9rieux SA
    • 17.3.6. QIAGEN N.V.
    • 17.3.7. Bio-Rad Laboratories, Inc.
    • 17.3.8. Siemens Healthineers AG
    • 17.3.9. Meridian Bioscience, Inc.
    • 17.3.10. Chembio Diagnostics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DENGUE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DENGUE TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DENGUE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DENGUE TESTING MARKET SIZE, BY SETTING, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DENGUE TESTING MARKET SIZE, BY SETTING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DENGUE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS DENGUE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL DENGUE TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. DENGUE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. DENGUE TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DENGUE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DENGUE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DENGUE TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DENGUE TESTING MARKET SIZE, BY IGG ANTIBODY TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DENGUE TESTING MARKET SIZE, BY IGG ANTIBODY TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DENGUE TESTING MARKET SIZE, BY IGG ANTIBODY TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DENGUE TESTING MARKET SIZE, BY IGG ANTIBODY TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DENGUE TESTING MARKET SIZE, BY IGG ANTIBODY TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DENGUE TESTING MARKET SIZE, BY IGG ANTIBODY TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DENGUE TESTING MARKET SIZE, BY IGM ANTIBODY TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DENGUE TESTING MARKET SIZE, BY IGM ANTIBODY TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DENGUE TESTING MARKET SIZE, BY IGM ANTIBODY TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DENGUE TESTING MARKET SIZE, BY IGM ANTIBODY TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DENGUE TESTING MARKET SIZE, BY IGM ANTIBODY TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DENGUE TESTING MARKET SIZE, BY IGM ANTIBODY TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 RAPID TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 RAPID TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 RAPID TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 RAPID TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 RAPID TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 RAPID TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DENGUE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DENGUE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DENGUE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DENGUE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DENGUE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DENGUE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DENGUE TESTING MARKET SIZE, BY COLLOIDAL GOLD ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DENGUE TESTING MARKET SIZE, BY COLLOIDAL GOLD ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DENGUE TESTING MARKET SIZE, BY COLLOIDAL GOLD ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DENGUE TESTING MARKET SIZE, BY COLLOIDAL GOLD ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DENGUE TESTING MARKET SIZE, BY COLLOIDAL GOLD ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DENGUE TESTING MARKET SIZE, BY COLLOIDAL GOLD ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DENGUE TESTING MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DENGUE TESTING MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DENGUE TESTING MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DENGUE TESTING MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DENGUE TESTING MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DENGUE TESTING MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DENGUE TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DENGUE TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DENGUE TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DENGUE TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DENGUE TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DENGUE TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DENGUE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DENGUE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DENGUE TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DENGUE TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DENGUE TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DENGUE TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DENGUE TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DENGUE TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DENGUE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DENGUE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DENGUE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DENGUE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DENGUE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DENGUE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DENGUE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DENGUE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DENGUE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DENGUE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DENGUE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DENGUE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DENGUE TESTING MARKET SIZE, BY READERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DENGUE TESTING MARKET SIZE, BY READERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DENGUE TESTING MARKET SIZE, BY READERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DENGUE TESTING MARKET SIZE, BY READERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DENGUE TESTING MARKET SIZE, BY READERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DENGUE TESTING MARKET SIZE, BY READERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DENGUE TESTING MARKET SIZE, BY THERMAL CYCLERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DENGUE TESTING MARKET SIZE, BY THERMAL CYCLERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DENGUE TESTING MARKET SIZE, BY THERMAL CYCLERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DENGUE TESTING MARKET SIZE, BY THERMAL CYCLERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DENGUE TESTING MARKET SIZE, BY THERMAL CYCLERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DENGUE TESTING MARKET SIZE, BY THERMAL CYCLERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DENGUE TESTING MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DENGUE TESTING MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DENGUE TESTING MARKET SIZE, BY SOFTWARE SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DENGUE TESTING MARKET SIZE, BY SOFTWARE SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DENGUE TESTING MARKET SIZE, BY SOFTWARE SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DENGUE TESTING MARKET SIZE, BY SOFTWARE SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DENGUE TESTING MARKET SIZE, BY SETTING, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DENGUE TESTING MARKET SIZE, BY CENTRAL LABORATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DENGUE TESTING MARKET SIZE, BY CENTRAL LABORATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DENGUE TESTING MARKET SIZE, BY CENTRAL LABORATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DENGUE TESTING MARKET SIZE, BY CENTRAL LABORATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DENGUE TESTING MARKET SIZE, BY CENTRAL LABORATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DENGUE TESTING MARKET SIZE, BY CENTRAL LABORATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DENGUE TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DENGUE TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL DENGUE TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL DENGUE TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL DENGUE TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL DENGUE TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL DENGUE TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL DENGUE TESTING MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL DENGUE TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL DENGUE TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL DENGUE TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL DENGUE TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL DENGUE TESTING MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL DENGUE TESTING MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL DENGUE TESTING MARKET SIZE, BY SERUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL DENGUE TESTING MARKET SIZE, BY SERUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL DENGUE TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL DENGUE TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL DENGUE TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL DENGUE TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL DENGUE TESTING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL DENGUE TESTING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL DENGUE TESTING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL DENGUE TESTING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL DENGUE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL DENGUE TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS DENGUE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS DENGUE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS DENGUE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS DENGUE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS DENGUE TESTING MARKET SIZE, BY SETTING, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY SETTING, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY SETTING, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SETTING, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPE DENGUE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPE DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPE DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPE DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPE DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPE DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPE DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPE DENGUE TESTING MARKET SIZE,